medigraphic.com
ISSN 1561-302X (Print)

2012, Number 4

<< Back Next >>

Rev cubana med 2012; 51 (4)

Correction of hyperphosphoremia in patients suffering chronic renal diseases and treated with long duration and high flux dialysis

Aties SM, Raola SME, Galbán RD, Ibars BEV, Magrans BC, Gutiérrez GF

Language: Spanish
References: 25
Page: 280-290
PDF size: 162.65 Kb.


ABSTRACT

Introduction: high flux hemodialysis causes major removal of big and small molecules, so the clearing increases and the treated people remarkably improves. Taking into account that excretion of phosphorus depends on its kinetics, this technique allows correcting it, mainly if combined with long duration and high frequency dialysis.
Objective: to evaluate the correction of hyperphosphoremia based on long duration high flux hemodialysis.
Methods: an experimental intervention study was conducted in two groups, namely, the study and the control groups in which 12 patients, who were selected by the simple random method, were distributed. They presented with high phosphorus content figures. Group I was treated with long duration high flux hemodialysis for 18 hours every week by using high flux polysulphone membrane dialyzers. Group II underwent conventional low flux hemodialysis for 12 hours a week. Both groups were clinically and humorally followed-up monthly. The primary and secondary response variables depending on the phosphorous, calcium, calcium phosphate product, KT/V, albumin, hemoglobin and morbidity levels were analyzed. Data were processed using SPPS statistical package, 15.0 version.
Results: the study group lowered the serum phosphorus by 0.36 mmol/L, calcium and calcium phosphate product decreased by 9.2 % and 23.90 % respectively at the end of the study. There was no correlation between the length of treatment (dialysis) and hyperphosphoremia; Spearman's non-parametric linear correlation was -0.09 and there was no statistical significance. Of the patients, 66.7 % had cramps and 50% had hypotension as morbidity.
Conclusions: long duration high flux hemodialysis reduces the serum phosphorus levels and improves albumin, calcium, calcium phosphate product metabolism and KT/V in patients on hemodialysis.


REFERENCES

  1. Martínez Fernández I, Saracho R. El fósforo y sus implicaciones clínicas. Nefrología. Suplemento Extraordinario 2009;29(5):41-50.

  2. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771-80.

  3. White CA, Jaffey J, MagnerP. Costo de aplicar las guías K-Doqui para metabolismo y enfermedad ósea a una cohorte de pacientes en terapia dialítica crónica: Kid Int. 2007;1(3):312-7.

  4. Maduell F. Eficacia depurativa de medianas y grandes moléculas en diferentes modalidades de hemodiálisis. Nefrología. 2005;25 Supl 2:15-8.

  5. Katopodis Kp, Chala A, Kaliouski E, Takouli L, Kalaitzidis R, Theodorou J, et al. Role of dialyzer membrane on the overall phosphate kinetics during hemodialysis. Blood Purif. 2005:23(5):359-64.

  6. Ferreira A. Hemodialise de alto fluxo. Será que vale la pena? Rev Port nefrol Hipert. 2004:17(3):121-7.

  7. Lorenzo Sellares V. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Nefrología. 2009; 29(Sup. Ext. 5):6-9.

  8. Torregrosa JV, Cannata AJ, Bover J, Caravaca F, Lorenzo V, Mar-Dusso AS, et al. SEN Guidelines. Recommendations of the Spanish Society of Nephrology for managing bone-mineral metabolic alterations in chronic renal disease patients. Nefrología. 2008;28 Supl 1:1-22.

  9. Dhingra R, Sullivan LM, Fox CS. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879-85.

  10. Peris A, Hernández J, Pons H, García E, Torregosa J, Sánchez J, et al. Kinetics of calcium, phosphate and magnesium and PTH variations during hemodiafiltration. Nefrología. 2007;27(5):594-8.

  11. Ward RA, Schmidtb, Hullin J, Hillebrand GT, Samtieben W. A comparison of on- line hemodiafiltration and high flux hemodialysis: a prospective clinical study. J Am Soc Nephrol. 2008;11:2344-50.

  12. Eloot S, Van Biessen W, Dhont A, Van de Wynkele H, Glorieux G, Verdonck P, et al. Impact of haemodialysis duration on the removal of uremic retention solutes. Kidney Int. 2008;73:765-70.

  13. Andrés E. ¿La hemodiálisis convencional es diálisis adecuada? Nefrología. 2005; 25 Supl 2: 121-9.

  14. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of diálisis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010-9.

  15. Steinman T. Serum albumin: Its significance in patients with ESRD. Sem Dial. 2000;13:404-8.

  16. Tattersall J, Canaud B, Heimburger O and European Renal Best Practice advisory Board. High-flux or low-flux dialysis: a position statement following publication of the Membrane Permeability Outcome study, 2007. Nephrol Dial Transplant. 2007;25(4):1230-2.

  17. Altman P, Barnett ME, Finn WF. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int. 2007;71(3):252-9.

  18. Torregrosa JC, Cannata Andia J, Caravaca F. Recomendaciones de la Sociedad Española de Nefrología para el Manejo de las alteraciones del metabolismo óseo- mineral de los pacientes con enfermedad renal crónica. Revista de Nefrologia 2011;31(Suppl.1):3-32.

  19. Locatelli F, Martin-Malo A, Hannedouche T. Membrane Permeability Outcome (MPO) study group: effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2009;20:645-54.

  20. Sampaio MS, Ruzany F, Dorigo DM, Suassuna JH. Phosphate Mass Removal during Hemodialysis: A Comparison between eKT/V-Matched Conventional and Extended Dialysis. Am J Nephrol. 2012;36(2):121-6.

  21. Mallol Domínguez A, Carratalá Chacón J, Folch Morro MJ, Renau Ortells E, Bueno Chiva C, Bort Castelló J, et al. Estudio comparativo de tres técnicas de hemodiálisis: AFB-K, hemodiafiltración y hemodiálisis de alto fl. Rev Soc Esp Enferm Nefrol. jul.-sep. 2009;12(3):179-84.

  22. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74(2):148-57.

  23. Patrier L, Dupuy AM, Granger Vallée A, Chalabi L, Morena M, Canaud B, et al. FGF-23 removal is improved by on-line high-efficiency hemodiafiltration compared to conventional high flux hemodialysis. J Nephrol. Apr 2012;27:0. doi: 10.5301/jn.5000150.

  24. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(5):1423-9.

  25. Chanveau P, Nguyen H, Combe C. Dialyser membrane permeability and survival in hemodialysis patient, Am J Kidney Div. 2005,46:564-71.




2020     |     www.medigraphic.com